Peptide Profile

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist

Overview

Composition

Synthetic polypeptide and first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Mechanism of Action

Mimics and amplifies the effects of incretin hormones by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting energy expenditure

Primary Effects

Produces substantial glycemic and weight improvements in large diabetes and obesity trial programs, with labeled uses expanding as evidence accumulates.

Discovery & Background

Developed by Eli Lilly to combine GIP and GLP-1 receptor activity in a single incretin-based therapy.

FDA approval in May 2022 as Mounjaro® for type 2 diabetes; November 2023 approval as Zepbound® for chronic weight management; late 2024 expansion for obstructive sleep apnea (OSA) in obesity

FDA-approved for type 2 diabetes, chronic weight management, and OSA in obesity; other uses remain off-label or investigational

Research Overview

Large Phase 3 programs SURPASS (diabetes) and SURMOUNT (obesity/weight management) demonstrated clinically meaningful glycemic and weight outcomes

01
SURPASS trials showed large HbA1c and body-weight reductions in type 2 diabetes
02
SURMOUNT trials showed substantial weight reduction in adults with obesity or overweight with comorbidities
03
Cardiovascular, liver-disease, and PCOS questions should be separated from the approved-label indications unless supported by indication-specific trial evidence
04
Head-to-head and real-world comparisons require attention to population, comparator, endpoint, and follow-up duration
05
Other uses such as NAFLD/MASLD/MASH or PCOS remain off-label or investigational

FDA-approved for type 2 diabetes, chronic weight management, and OSA in obesity; other uses (e.g., NAFLD, PCOS) remain off-label or investigational

Safety Considerations

Monitoring

Blood glucose/HbA1c
Weight
Lipids
Liver function
Symptom patterns

Side Effects

Gastrointestinal (Common)

Nausea
Peak during escalation phase
Vomiting, diarrhea, constipation, or abdominal discomfort

Local

Local reactions can occur with approved products.

Rare but Serious

Pancreatitis
Gallbladder issues
Thyroid concerns (boxed warning for C-cell tumors in rodents)

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Hypersensitivity to tirzepatide or any component

Educational Notice

Tirzepatide has strong clinical evidence for approved type 2 diabetes, chronic weight-management, and OSA-in-obesity indications. Claims outside those labels require indication-specific evidence review. Compounded or research-market formulations lack the same regulatory oversight as approved products.

References